• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

莫努匹韦的计算分析。

Computational Analysis of Molnupiravir.

机构信息

«Advanced Materials for Industry and Biomedicine» Laboratory, Kurgan State University, Sovetskaya Str. 63/4, 640020 Kurgan, Russia.

Center for Enterprise Relations, Ural Federal University Named after the First President of Russia B.N. Yeltsin, Mira Str. 19, 620002 Ekaterinburg, Russia.

出版信息

Int J Mol Sci. 2022 Jan 28;23(3):1508. doi: 10.3390/ijms23031508.

DOI:10.3390/ijms23031508
PMID:35163429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8835990/
Abstract

In this work, we report in-depth computational studies of three plausible tautomeric forms, generated through the migration of two acidic protons of the -hydroxylcytosine fragment, of molnupiravir, which is emerging as an efficient drug to treat COVID-19. The DFT calculations were performed to verify the structure of these tautomers, as well as their electronic and optical properties. Molecular docking was applied to examine the influence of the structures of the keto-oxime, keto-hydroxylamine and hydroxyl-oxime tautomers on a series of the SARS-CoV-2 proteins. These tautomers exhibited the best affinity behavior (-9.90, -7.90, and -9.30 kcal/mol, respectively) towards RdRp-RTR and Nonstructural protein 3 (nsp3_range 207-379-MES).

摘要

在这项工作中,我们报告了对莫那比拉韦的三种可能互变异构形式的深入计算研究,这些互变异构形式是通过 - 羟基胞嘧啶片段的两个酸性质子的迁移生成的,莫那比拉韦正在成为治疗 COVID-19 的有效药物。进行了 DFT 计算以验证这些互变异构体的结构以及它们的电子和光学性质。应用分子对接来检查酮肟、酮羟肟和羟肟互变异构体的结构对一系列 SARS-CoV-2 蛋白的影响。这些互变异构体对 RdRp-RTR 和非结构蛋白 3(nsp3_range 207-379-MES)表现出最佳的亲和力行为(分别为-9.90、-7.90 和-9.30 kcal/mol)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/549579fc4cde/ijms-23-01508-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/80d26abd0d23/ijms-23-01508-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/23384cb7206b/ijms-23-01508-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/484b1350f427/ijms-23-01508-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/6ce019bf9be8/ijms-23-01508-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/ec0972466f5b/ijms-23-01508-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/73071fc5662b/ijms-23-01508-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/fe49dbdc38f6/ijms-23-01508-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/d6f604cd9845/ijms-23-01508-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/549579fc4cde/ijms-23-01508-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/80d26abd0d23/ijms-23-01508-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/23384cb7206b/ijms-23-01508-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/484b1350f427/ijms-23-01508-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/6ce019bf9be8/ijms-23-01508-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/ec0972466f5b/ijms-23-01508-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/73071fc5662b/ijms-23-01508-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/fe49dbdc38f6/ijms-23-01508-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/d6f604cd9845/ijms-23-01508-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/988c/8835990/549579fc4cde/ijms-23-01508-g009.jpg

相似文献

1
Computational Analysis of Molnupiravir.莫努匹韦的计算分析。
Int J Mol Sci. 2022 Jan 28;23(3):1508. doi: 10.3390/ijms23031508.
2
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.莫努匹拉韦诱导的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)诱变机制。
Nat Struct Mol Biol. 2021 Sep;28(9):740-746. doi: 10.1038/s41594-021-00651-0. Epub 2021 Aug 11.
3
Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets.对莫努匹韦(EIDD-2801)的比较对接和分子动力学研究:对流感和 SARS-CoV-2 蛋白靶标新型作用机制的影响。
J Biomol Struct Dyn. 2024 Sep;42(15):8202-8214. doi: 10.1080/07391102.2023.2267696. Epub 2023 Oct 9.
4
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.莫努匹韦的发现、研发与专利趋势:一种有前景的 COVID-19 口服治疗药物
Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.
5
Molnupiravir: coding for catastrophe.莫努匹拉韦:引发灾难的编码。
Nat Struct Mol Biol. 2021 Sep;28(9):706-708. doi: 10.1038/s41594-021-00657-8.
6
A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2.莫努匹拉韦活性代谢物与野生型和新冠病毒Delta变异株AY.4的RNA依赖性RNA聚合酶结合机制的计算比较分析。
J Cell Biochem. 2022 Apr;123(4):807-818. doi: 10.1002/jcb.30226. Epub 2022 Feb 7.
7
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.一项关于全球针对 SARS-CoV-2 干预措施的系统评价:从药物再利用到莫努匹韦批准。
Drug Des Devel Ther. 2022 Mar 15;16:685-715. doi: 10.2147/DDDT.S354841. eCollection 2022.
8
Potential COVID-19 Drug Candidates Based on Diazinyl-Thiazol-Imine Moieties: Synthesis and Greener Pastures Biological Study.基于二嗪基-噻唑-亚胺部分的潜在COVID-19候选药物:合成及生物活性研究
Molecules. 2022 Jan 13;27(2):488. doi: 10.3390/molecules27020488.
9
An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir.一种工程化的胞嘧啶脱氨酶用于生物催化生产新冠病毒抗病毒药物 Molnupiravir 的关键中间体。
J Am Chem Soc. 2022 Mar 9;144(9):3761-3765. doi: 10.1021/jacs.1c11048. Epub 2022 Feb 28.
10
A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy.从合成到紧急使用授权:莫努匹韦作为 COVID-19 疗法的路径。
Bioorg Chem. 2024 Jun;147:107379. doi: 10.1016/j.bioorg.2024.107379. Epub 2024 Apr 17.

引用本文的文献

1
A comparative study of electropolymerization and photopolymerization for the determination of molnupiravir and their application in an electrochemical sensor via computationally designed molecularly imprinted polymers.电聚合和光聚合的比较研究及其在通过计算设计的分子印迹聚合物在电化学传感器中对莫努匹拉韦的测定及其应用。
Mikrochim Acta. 2024 Apr 17;191(5):270. doi: 10.1007/s00604-024-06353-w.
2
Unraveling DDIT4 in the VDR-mTOR pathway: a novel target for drug discovery in diabetic kidney disease.解析维生素D受体-雷帕霉素靶蛋白通路中的DDIT4:糖尿病肾病药物研发的新靶点
Front Pharmacol. 2024 Mar 19;15:1344113. doi: 10.3389/fphar.2024.1344113. eCollection 2024.
3

本文引用的文献

1
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.一项评估莫努匹韦在 COVID-19 患者中的 2a 期临床试验显示,其可加速 SARS-CoV-2 RNA 清除并消除具有感染性的病毒。
Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430.
2
RdRp inhibitors and COVID-19: Is molnupiravir a good option?RdRp 抑制剂与 COVID-19:莫那比拉韦是一个好选择吗?
Biomed Pharmacother. 2022 Feb;146:112517. doi: 10.1016/j.biopha.2021.112517. Epub 2021 Dec 9.
3
A tale of two antiviral targets - and the COVID-19 drugs that bind them.
Thermodynamic and Kinetic Characteristics of Molnupiravir Tautomers and Its Complexes with RNA Purine Bases as an Explanation of the Possible Mechanism of Action of This Novel Antiviral Medicine: A Quantum-Chemical Study.
莫努匹拉韦互变异构体及其与RNA嘌呤碱基复合物的热力学和动力学特征,以解释这种新型抗病毒药物可能的作用机制:一项量子化学研究
J Org Chem. 2023 Oct 6;88(19):14048-14064. doi: 10.1021/acs.joc.3c01580. Epub 2023 Sep 27.
4
Preferability of Molnupiravir, an Anti-COVID-19 Drug, toward Purine Nucleosides: A Quantum Mechanical Study.抗新冠病毒药物莫努匹拉韦对嘌呤核苷的偏好性:一项量子力学研究
ACS Omega. 2023 Jul 18;8(30):27553-27565. doi: 10.1021/acsomega.3c03215. eCollection 2023 Aug 1.
5
Chiral discrimination of cyclodecapeptide to anti-COVID-19 clinical candidates: a theoretical study.环十肽对抗COVID-19临床候选药物的手性识别:一项理论研究
Struct Chem. 2023 Mar 14:1-11. doi: 10.1007/s11224-023-02149-5.
6
Copper(II) Chelates of Schiff Bases Enriched with Aliphatic Fragments: Synthesis, Crystal Structure, In Silico Studies of ADMET Properties and a Potency against a Series of SARS-CoV-2 Proteins.富含脂肪族片段的席夫碱铜(II)螯合物:合成、晶体结构、ADMET性质的计算机模拟研究以及对一系列SARS-CoV-2蛋白的活性
Pharmaceuticals (Basel). 2023 Feb 14;16(2):286. doi: 10.3390/ph16020286.
7
A Novel Ambroxol-Derived Tetrahydroquinazoline with a Potency against SARS-CoV-2 Proteins.一种新型氨溴索衍生的四氢喹唑啉,对 SARS-CoV-2 蛋白具有抑制活性。
Int J Mol Sci. 2023 Feb 28;24(5):4660. doi: 10.3390/ijms24054660.
8
Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.莫努匹拉韦:一种针对新冠病毒变异株的多功能前药。
Metabolites. 2023 Feb 20;13(2):309. doi: 10.3390/metabo13020309.
9
A novel coumarin-triazole-thiophene hybrid: synthesis, characterization, ADMET prediction, molecular docking and molecular dynamics studies with a series of SARS-CoV-2 proteins.一种新型香豆素-三唑-噻吩杂化物:合成、表征、ADMET预测、分子对接以及与一系列SARS-CoV-2蛋白的分子动力学研究
J Chem Sci (Bangalore). 2023;135(1):6. doi: 10.1007/s12039-022-02127-0. Epub 2023 Jan 18.
10
In Vitro and In Silico Studies for the Identification of Potent Metabolites of Some High-Altitude Medicinal Plants from Nepal Inhibiting SARS-CoV-2 Spike Protein.体外和计算机模拟研究鉴定来自尼泊尔的一些高海拔药用植物的有效代谢物抑制 SARS-CoV-2 刺突蛋白
Molecules. 2022 Dec 15;27(24):8957. doi: 10.3390/molecules27248957.
两个抗病毒靶点的故事——以及与之结合的新冠病毒药物。
Nat Rev Drug Discov. 2022 Jan;21(1):3-5. doi: 10.1038/d41573-021-00202-8.
4
The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era.疫苗接种后时代强效口服抗新冠病毒药物的出现。
Lancet Microbe. 2022 Feb;3(2):e91. doi: 10.1016/S2666-5247(21)00278-0. Epub 2021 Nov 25.
5
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.Molnupiravir 和 Favipiravir 的联合治疗可增强 SARS-CoV-2 仓鼠感染模型中的抗病毒疗效。
EBioMedicine. 2021 Oct;72:103595. doi: 10.1016/j.ebiom.2021.103595. Epub 2021 Sep 24.
6
Molnupiravir: coding for catastrophe.莫努匹拉韦:引发灾难的编码。
Nat Struct Mol Biol. 2021 Sep;28(9):706-708. doi: 10.1038/s41594-021-00657-8.
7
Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.刺突蛋白上对 SARS-CoV-2 进化的关键突变导致变异株逃避恢复期血浆和 RBD 特异性单克隆抗体的中和作用。
Front Immunol. 2021 Aug 17;12:693775. doi: 10.3389/fimmu.2021.693775. eCollection 2021.
8
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.莫努匹拉韦诱导的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)诱变机制。
Nat Struct Mol Biol. 2021 Sep;28(9):740-746. doi: 10.1038/s41594-021-00651-0. Epub 2021 Aug 11.
9
AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings.AutoDock Vina 1.2.0:新的对接方法、扩展的力场及Python绑定
J Chem Inf Model. 2021 Aug 23;61(8):3891-3898. doi: 10.1021/acs.jcim.1c00203. Epub 2021 Jul 19.
10
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.口服给药的MK-4482在叙利亚仓鼠模型中抑制新冠病毒复制。
Nat Commun. 2021 Apr 16;12(1):2295. doi: 10.1038/s41467-021-22580-8.